Yükleniyor... / Loading...
This study aims to collect real-world information about treatment with the drug Brigatinib in Chinese patients with non-small cell lung cancer. It enrolled patients aged 18 and older with advanced or metastatic disease and a confirmed ALK gene rearrangement who received Brigatinib as first-line treatment. It is a trial without an assigned phase and is currently not recruiting but ongoing (active, not recruiting).
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria 1. Age ≥ 18 years. 2. Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC. 3. Participants with ALK gene rearrangement confirmed by local hospital medical records. 4. Participants who received brigatinib since September 1, 2022 as first line treatment confirmed by medical records. 5. Participants who have at least one medical record after the start of brigatinib treatment. Exclusion Criteria 1. Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment. 2. Previously received any other TKIs, including ALK-targeted TKIs. 3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease. 4. Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.